Compare CELC & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CELC | CUZ |
|---|---|---|
| Founded | 2011 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.9B |
| IPO Year | 2017 | 1994 |
| Metric | CELC | CUZ |
|---|---|---|
| Price | $53.29 | $28.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $150.85 | $33.45 |
| AVG Volume (30 Days) | 920.9K | ★ 1.4M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.11 |
| Revenue | N/A | ★ $993,816,000.00 |
| Revenue This Year | N/A | $6.76 |
| Revenue Next Year | $1,921.71 | $2.45 |
| P/E Ratio | ★ N/A | $262.18 |
| Revenue Growth | N/A | ★ 16.00 |
| 52 Week Low | $53.54 | $21.03 |
| 52 Week High | $151.02 | $32.95 |
| Indicator | CELC | CUZ |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 46.72 |
| Support Level | N/A | $27.31 |
| Resistance Level | $72.76 | $29.41 |
| Average True Range (ATR) | 4.24 | 0.69 |
| MACD | -1.03 | -0.13 |
| Stochastic Oscillator | 0.16 | 18.67 |
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.